within Pharmacolibrary.Drugs.ATC.C;

model C01BA08_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 2.9166666666666665,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Prajmaline is an antiarrhythmic drug of the class Ia, developed from the plant alkaloid ajmaline. It is used to treat certain cardiac arrhythmias, such as ventricular and supraventricular tachycardias. Prajmaline is not widely approved or used in clinical practice today, with usage mainly reported in some European countries and limited global distribution.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adults (male and female) following oral administration.</p><h4>References</h4><ol><li><a href='https://dx.doi.org/10.1007/BF00542008'>10.1007/BF00542008</a> PK parameters summarized from healthy adults after single oral administration, based on reported data in 'Pharmacokinetics and metabolism of prajmaline in man', Eur. J. Clin. Pharmacol (1979) 15: 377â€“384. Oral bioavailability ~85% and absorption rate and Tlag are estimated from concentration-time profiles reported in the reference.</li></ol></body></html>",
    revisions = "<html><body><ul><li>03/06/2025 model generated from PK parameters and knowledge obtained by LLM gpt-4.1 and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01BA08_1;
